Literature DB >> 15937115

Thrombin inhibitors identified by computer-assisted multiparameter design.

Daniel Riester1, Frank Wirsching, Gabriela Salinas, Martina Keller, Michael Gebinoga, Stefan Kamphausen, Christian Merkwirth, Ruediger Goetz, Martin Wiesenfeldt, Jörg Stürzebecher, Wolfram Bode, Rainer Friedrich, Marcel Thürk, Andreas Schwienhorst.   

Abstract

Here, we present a series of thrombin inhibitors that were generated by using powerful computer-assisted multiparameter optimization process. The process was organized in design cycles, starting with a set of randomly chosen molecules. Each cycle combined combinatorial synthesis, multiparameter characterization of compounds in a variety of bioassays, and algorithmic processing of the data to devise a set of compounds to be synthesized in the next cycle. The identified lead compounds exhibited thrombin inhibitory constants in the lower nanomolar range. They are by far the most selective synthetic thrombin inhibitors, with selectivities of >100,000-fold toward other proteases such as Factor Xa, Factor XIIa, urokinase, plasmin, and Plasma kallikrein. Furthermore, these compounds exhibit a favorable profile, comprising nontoxicity, high metabolic stability, low serum protein binding, good solubility, high anticoagulant activity, and a slow and exclusively renal elimination from the circulation in a rat model. Finally, x-ray crystallographic analysis of a thrombin-inhibitor complex revealed a binding mode with a neutral moiety in the S1 pocket of thrombin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937115      PMCID: PMC1150832          DOI: 10.1073/pnas.0501983102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks.

Authors:  G Schneider; M L Lee; M Stahl; P Schneider
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

Review 3.  Advances in the development of thrombin inhibitors.

Authors:  T Steinmetzer; J Hauptmann; J Sturzebecher
Journal:  Expert Opin Investig Drugs       Date:  2001-05       Impact factor: 6.206

4.  Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

Authors:  E Skrzypczak-Jankun; V E Carperos; K G Ravichandran; A Tulinsky; M Westbrook; J M Maraganore
Journal:  J Mol Biol       Date:  1991-10-20       Impact factor: 5.469

5.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

6.  Development of plasma kallikrein selective inhibitors.

Authors:  Y Okada; Y Tsuda; M Tada; K Wanaka; A Hijikata-Okunomiya; U Okamoto; S Okamoto
Journal:  Biopolymers       Date:  1999       Impact factor: 2.505

7.  Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.

Authors:  D Gustafsson; T Antonsson; R Bylund; U Eriksson; E Gyzander; I Nilsson; M Elg; C Mattsson; J Deinum; S Pehrsson; O Karlsson; A Nilsson; H Sörensen
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

8.  Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.

Authors:  E Marsh Lyle; S D Lewis; E D Lehman; S J Gardell; S L Motzel; J J Lynch
Journal:  Thromb Haemost       Date:  1998-03       Impact factor: 5.249

9.  Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats.

Authors:  Jörg Hauptmann; Torsten Steinmetzer; Helmut Vieweg; Peter Wikström; Jürg Stürzebecher
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

10.  Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.

Authors:  W A Schumacher; N Balasubramanian; D R St Laurent; S M Seiler
Journal:  Eur J Pharmacol       Date:  1994-07-01       Impact factor: 4.432

View more
  6 in total

1.  Why Some Targets Benefit from beyond Rule of Five Drugs.

Authors:  Megan Egbert; Adrian Whitty; György M Keserű; Sandor Vajda
Journal:  J Med Chem       Date:  2019-06-26       Impact factor: 7.446

2.  Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids.

Authors:  Jacob R Immel; Maheshwerreddy Chilamari; Steven Bloom
Journal:  Chem Sci       Date:  2021-06-30       Impact factor: 9.969

3.  VitAL: Viterbi algorithm for de novo peptide design.

Authors:  E Besray Unal; Attila Gursoy; Burak Erman
Journal:  PLoS One       Date:  2010-06-02       Impact factor: 3.240

4.  Molecular evolution of a peptide GPCR ligand driven by artificial neural networks.

Authors:  Sebastian Bandholtz; Jörg Wichard; Ronald Kühne; Carsten Grötzinger
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

Review 5.  Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).

Authors:  Peter Goettig; Viktor Magdolen; Hans Brandstetter
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

6.  Evolutionary Pareto-optimization of stably folding peptides.

Authors:  Wolfram Gronwald; Tim Hohm; Daniel Hoffmann
Journal:  BMC Bioinformatics       Date:  2008-02-19       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.